Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EDSA NASDAQ:INNT NASDAQ:NOVN OTCMKTS:PVCT NASDAQ:SEEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDSAEdesa Biotech$2.18-0.9%$2.02$1.55▼$5.59$15.45M0.39493,192 shs33,475 shsINNTInnovate Biopharmaceuticals$0.97$0.37▼$1.67$8K-0.39525,982 shs1,375 shsNOVNNovan$0.00$0.08▼$3.33$2.64M-0.06602,421 shs7.19 million shsPVCTProvectus Biopharmaceuticals$0.07-0.4%$0.08$0.04▼$0.15$30.76M0.75152,722 shs131,010 shsSEELSeelos Therapeutics$0.00$0.37▼$698.88N/A1.94174,745 shs2 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDSAEdesa Biotech+5.26%+6.80%+14.58%-5.38%-48.36%INNTInnovate Biopharmaceuticals0.00%0.00%0.00%0.00%0.00%NOVNNovan0.00%0.00%0.00%0.00%0.00%PVCTProvectus Biopharmaceuticals-4.31%-2.40%-0.68%-25.69%-37.35%SEELSeelos Therapeutics0.00%0.00%0.00%0.00%-99.99%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEDSAEdesa Biotech2.2623 of 5 stars2.05.00.00.03.51.70.6INNTInnovate BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ANOVNNovanN/AN/AN/AN/AN/AN/AN/AN/APVCTProvectus BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASEELSeelos TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDSAEdesa Biotech 4.00Strong Buy$5.00129.36% UpsideINNTInnovate Biopharmaceuticals 0.00N/AN/AN/ANOVNNovan 0.00N/AN/AN/APVCTProvectus Biopharmaceuticals 0.00N/AN/AN/ASEELSeelos Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest INNT, NOVN, PVCT, EDSA, and SEEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025EDSAEdesa BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$5.00(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDSAEdesa BiotechN/AN/AN/AN/A$0.61 per shareN/AINNTInnovate BiopharmaceuticalsN/AN/AN/AN/A($0.27) per shareN/ANOVNNovan$24.71M0.00N/AN/A$0.19 per share0.00PVCTProvectus Biopharmaceuticals$620K49.42N/AN/A($0.01) per share-7.29SEELSeelos Therapeutics$2.20M0.00N/AN/A($437.92) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDSAEdesa Biotech-$6.17M-$1.59N/AN/AN/AN/A-187.01%-78.72%8/8/2025 (Estimated)INNTInnovate Biopharmaceuticals-$27.05MN/AN/AN/AN/AN/AN/A-234.42%N/ANOVNNovan-$31.31M-$1.32N/AN/AN/A-128.61%-700.28%-39.58%N/APVCTProvectus Biopharmaceuticals-$4.76MN/A0.00∞N/A-815.81%N/A-644.80%8/11/2025 (Estimated)SEELSeelos Therapeutics-$37.88MN/A0.00N/AN/A203.13%N/A-431.47%N/ALatest INNT, NOVN, PVCT, EDSA, and SEEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025N/AEDSAEdesa Biotech-$0.23N/AN/AN/AN/AN/A5/14/2025Q2 2025EDSAEdesa Biotech-$0.30-$0.30N/A-$0.30N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEDSAEdesa BiotechN/AN/AN/AN/AN/AINNTInnovate BiopharmaceuticalsN/AN/AN/AN/AN/ANOVNNovanN/AN/AN/AN/AN/APVCTProvectus BiopharmaceuticalsN/AN/AN/AN/AN/ASEELSeelos TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDSAEdesa BiotechN/A15.7215.72INNTInnovate BiopharmaceuticalsN/A0.350.35NOVNNovanN/A0.740.72PVCTProvectus BiopharmaceuticalsN/A0.110.11SEELSeelos TherapeuticsN/A0.080.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDSAEdesa Biotech5.50%INNTInnovate Biopharmaceuticals5.88%NOVNNovan14.51%PVCTProvectus Biopharmaceuticals0.05%SEELSeelos Therapeutics23.37%Insider OwnershipCompanyInsider OwnershipEDSAEdesa Biotech22.60%INNTInnovate Biopharmaceuticals7.90%NOVNNovan1.30%PVCTProvectus Biopharmaceuticals12.80%SEELSeelos Therapeutics1.08%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDSAEdesa Biotech207.02 million5.44 millionNot OptionableINNTInnovate Biopharmaceuticals841.33 millionN/ANot OptionableNOVNNovan9028.02 million27.65 millionNot OptionablePVCTProvectus Biopharmaceuticals4420.28 million366.48 millionNot OptionableSEELSeelos Therapeutics20372,000368,000OptionableINNT, NOVN, PVCT, EDSA, and SEEL HeadlinesRecent News About These CompaniesSeelos Therapeutics Stock Price HistoryJune 4, 2025 | investing.comPsychedelic stocks rise as FDA chief’s comments seen favorable to industryMay 20, 2025 | msn.comJ&J builds case for antidepressant Spravato with head-to-head trialMarch 15, 2025 | pharmaphorum.comPPsychedelic drug developer Lykos could get lifeline from former Tesla board memberJanuary 10, 2025 | msn.comSeelos Therapeutics, Inc. (SEELQ)December 11, 2024 | finance.yahoo.comSeelos Therapeutics Inc SEELQNovember 27, 2024 | morningstar.comMAfter ALS trial misses mark, Seelos has filed for bankruptcyNovember 23, 2024 | fiercebiotech.comFSeelos Announces Second Postponement of its Annual Meeting of StockholdersOctober 24, 2024 | prnewswire.comSeelos Therapeutics Delisted From Nasdaq, Will Transition To OTC MarketOctober 16, 2024 | benzinga.comSeelos gets Nasdaq delisting noticeOctober 15, 2024 | msn.comSeelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter MarketOctober 15, 2024 | prnewswire.comSeelos Therapeutics Inc (SEEL) Stock: Analyzing Its Quiet PowerOctober 5, 2024 | bovnews.comBSeelos Therapeutics Inc (SEEL) Stock: More Robust Than the Numbers Suggest?September 27, 2024 | bovnews.comBSeelos Announces Postponement of its Annual Meeting of StockholdersSeptember 26, 2024 | prnewswire.comSeelos Therapeutics, Inc.: Seelos Therapeutics Announces 1-for-16 Reverse Stock SplitSeptember 25, 2024 | finanznachrichten.deSeelos Therapeutics to execute 1-for-16 reverse stock splitSeptember 25, 2024 | msn.comSeelos Therapeutics Announces 1-for-16 Reverse Stock SplitSeptember 25, 2024 | prnewswire.comSeelos Therapeutics (NASDAQ:SEEL) Stock Quotes, Forecast and News SummarySeptember 25, 2024 | benzinga.comSeelos Therapeutics (NASDAQ:SEEL) Stock, Short Interest ReportSeptember 25, 2024 | benzinga.comSeelos Therapeutics (SEEL) Soars: What’s Driving This Dramatic Stock Surge?September 24, 2024 | bovnews.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINNT, NOVN, PVCT, EDSA, and SEEL Company DescriptionsEdesa Biotech NASDAQ:EDSA$2.18 -0.02 (-0.91%) Closing price 03:57 PM EasternExtended Trading$2.14 -0.04 (-1.79%) As of 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.Innovate Biopharmaceuticals NASDAQ:INNTInnovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.Novan NASDAQ:NOVNNovan, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Durham, North Carolina.Provectus Biopharmaceuticals OTCMKTS:PVCT$0.07 0.00 (-0.41%) As of 02:59 PM EasternProvectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.Seelos Therapeutics NASDAQ:SEELSeelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Fastenal Surges After Earnings Beat, Tariff Risks Loom Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
